JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Low-dose fenfluramine as an effective treatment option for 'atypical' Dravet syndrome

  • 0Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, 886, Urushiyama, Aoi-ku, Shizuoka 420-8688, Japan.
Epilepsy & Behavior Reports +

|

October 21, 2024

|

October 21, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Dravet syndrome (DS) can present atypically. A rare case highlights effective fenfluramine treatment for seizures and cognitive improvement in a patient without genetic mutations and with abnormal MRI findings.

Area Of Science

  • Neurology
  • Genetics
  • Pediatric Epilepsy

Background

  • Dravet syndrome (DS) is a severe epilepsy characterized by refractory seizures and intellectual disability.
  • Typical DS diagnosis involves genetic mutations, recurrent status epilepticus, and normal brain MRI.
  • Antiseizure medication resistance is a hallmark of Dravet syndrome.

Observation

  • A rare case of DS in a 14-year-old girl with atypical features is presented.
  • The patient lacked typical genetic mutations and had only one episode of status epilepticus.
  • Brain MRI revealed abnormal findings, deviating from typical DS presentations.

Findings

  • Despite diagnostic challenges due to negative genetic testing, fenfluramine (FFA) was initiated.
  • Low-dose, long-term fenfluramine treatment effectively controlled seizures in this atypical DS case.
  • Significant cognitive and functional improvements were observed following FFA treatment.

Implications

  • This case expands the understanding of Dravet syndrome diagnostic variability.
  • It underscores the potential efficacy of fenfluramine in atypical DS presentations.
  • Highlights the importance of considering fenfluramine even with non-traditional DS markers.

Keywords:

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein 01:20

258

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antidepressant Drugs: MAOIs and Other Agents 01:23

196

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antiepileptic Drugs: Glutamate Antagonists 01:14

285

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Drugs for Treatment of Diarrhea-Predominant IBS 01:17

149

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Antiepileptic Drugs: Potassium Channel Activators 01:20

147

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators 01:18

336

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...